Your browser doesn't support javascript.
loading
Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.
Miyamoto, Sho; Kuroda, Yudai; Kanno, Takayuki; Ueno, Akira; Shiwa-Sudo, Nozomi; Iwata-Yoshikawa, Naoko; Sakai, Yusuke; Nagata, Noriyo; Arashiro, Takeshi; Ainai, Akira; Moriyama, Saya; Kishida, Noriko; Watanabe, Shinji; Nojima, Kiyoko; Seki, Yohei; Mizukami, Takuo; Hasegawa, Hideki; Ebihara, Hideki; Fukushi, Shuetsu; Takahashi, Yoshimasa; Maeda, Ken; Suzuki, Tadaki.
Afiliação
  • Miyamoto S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kuroda Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kanno T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ueno A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Shiwa-Sudo N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Iwata-Yoshikawa N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Sakai Y; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nagata N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Arashiro T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ainai A; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Moriyama S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kishida N; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Watanabe S; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Nojima K; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Seki Y; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Mizukami T; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Hasegawa H; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Ebihara H; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Fukushi S; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Takahashi Y; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Maeda K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki T; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
iScience ; 26(5): 106694, 2023 May 19.
Article em En | MEDLINE | ID: mdl-37124417
ABSTRACT
Evaluating the serum cross-neutralization responses after breakthrough infection with various SARS-CoV-2 variants provides valuable insight for developing variant-proof COVID-19 booster vaccines. However, fairly comparing the impact of breakthrough infections with distinct epidemic timing on cross-neutralization responses, influenced by the exposure interval between vaccination and infection, is challenging. To compare the impact of pre-Omicron to Omicron breakthrough infection, we estimated the effects on cross-neutralizing responses by the exposure interval using Bayesian hierarchical modeling. The saturation time required to generate saturated cross-neutralization responses differed by variant, with variants more antigenically distant from the ancestral strain requiring longer intervals of 2-4 months. The breadths of saturated cross-neutralization responses to Omicron lineages were comparable in pre-Omicron and Omicron breakthrough infections. Our results highlight the importance of vaccine dosage intervals of 4 months or longer, regardless of the antigenicity of the exposed antigen, to maximize the breadth of serum cross-neutralization covering SARS-CoV-2 Omicron lineages.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
...